Adenosine A2A-R Inhibitors

XCC is a non-selective adenosine receptor antagonist, similar to XAC. It also inhibits adenosine's effects on both ADORA1 and ADORA2A receptors.

Reversine functions as a selective antagonist of the adenosine A2A receptor, exhibiting unique electrostatic interactions that disrupt receptor activation. Its molecular structure facilitates specific van der Waals forces, contributing to a rapid dissociation rate from the receptor. This compound's ability to induce conformational changes in the receptor enhances its selectivity, allowing for targeted modulation of intracellular signaling cascades. The compound's distinct binding affinity influences downstream effects on cellular behavior.

This compound is a non-selective adenosine receptor antagonist that includes both ADORA1 and ADORA2A receptors. It competitively inhibits adenosine bindin

Istradefylline is a selective A2A-R antagonist that reduces A2A-R activation, potentially used in Parkinson's disease therapy.

PSB 1115 is a potent and selective ADORA2A antagonist. It specifically targets the ADORA2A receptor and blocks its activation.

CGS 15943 is a non-selective adenosine receptor antagonist, affecting both ADORA1 and ADORA2A receptors. It competitively binds to adenosine receptors, blocking their activation.